Eli Lilly’s psychedelic deal carries a US$3.8bn headline, but the fine print tells the real story
Eli Lilly’s AtaiBeckley deal brings psychedelic medicine into big pharma’s M&A race, but Phase 3 data and rescheduling still decide its value.
Pharma & Biotech